000277758 001__ 277758
000277758 005__ 20240229155022.0
000277758 0247_ $$2doi$$a10.3324/haematol.2023.282912
000277758 0247_ $$2pmid$$apmid:37470150
000277758 0247_ $$2ISSN$$a0390-6078
000277758 0247_ $$2ISSN$$a1592-8721
000277758 0247_ $$2altmetric$$aaltmetric:158335949
000277758 037__ $$aDKFZ-2023-01475
000277758 041__ $$aEnglish
000277758 082__ $$a610
000277758 1001_ $$aShahswar, Rabia$$b0
000277758 245__ $$aFludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.
000277758 260__ $$aPavia$$bFerrata Storti Foundation$$c2024
000277758 3367_ $$2DRIVER$$aarticle
000277758 3367_ $$2DataCite$$aOutput Types/Journal article
000277758 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1704806592_20279
000277758 3367_ $$2BibTeX$$aARTICLE
000277758 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277758 3367_ $$00$$2EndNote$$aJournal Article
000277758 500__ $$a2024 Jan 1;109(1):72-83
000277758 520__ $$aTreatment options for relapsed and refractory acute myeloid leukemia patients (R/R AML) are limited. This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) with or without venetoclax in patients with R/R AML. Thirty-seven and 81 patients received one course FLA-IDA with or without a 7-day course of venetoclax, respectively. The overall response rate (ORR) was significantly higher in FLAVIDA compared to FLA-IDA treated patients (78% vs. 47%; P=0.001), while MRD was negative at a similar proportion in responding patients (50% vs. 57%), respectively. Eightyone percent and 79% of patients proceeded to allogeneic hematopoietic cell transplantation (alloHCT) or donor lymphocyte infusion (DLI) after FLAVIDA and FLA-IDA, respectively. Event-free and overall survival were similar in FLAVIDA and FLA-IDA treated patients. Refractory patients could be salvaged more successfully after FLA-IDA compared to FLAVIDA pretreatment. Neutrophil and platelet recovery times were similar in the venetoclax and the control group. In conclusion, short-term venetoclax in combination with FLA-IDA represents an effective treatment regimen in R/R AML identifying chemosensitive patients rapidly and inducing MRD negative remission in a high proportion of R/R AML patients.
000277758 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277758 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277758 7001_ $$aBeutel, Gernot$$b1
000277758 7001_ $$aGabdoulline, Razif$$b2
000277758 7001_ $$aSchwarzer, Adrian$$b3
000277758 7001_ $$aKloos, Arnold$$b4
000277758 7001_ $$aKoenecke, Christian$$b5
000277758 7001_ $$aStadler, Michael$$b6
000277758 7001_ $$aGohring, Gudrun$$b7
000277758 7001_ $$aBehrens, Yvonne Lisa$$b8
000277758 7001_ $$aLi, Zhixiong$$b9
000277758 7001_ $$aDallmann, Louisa-Kristin$$b10
000277758 7001_ $$aKlement, Piroska$$b11
000277758 7001_ $$aAlbert, Catherin$$b12
000277758 7001_ $$aWichmann, Martin$$b13
000277758 7001_ $$aAlwie, Yasmine$$b14
000277758 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b15$$udkfz
000277758 7001_ $$aSaadati, Maral$$b16
000277758 7001_ $$aGanser, Arnold$$b17
000277758 7001_ $$aThol, Felicitas$$b18
000277758 7001_ $$aHeuser, Michael$$b19
000277758 773__ $$0PERI:(DE-600)2805244-4$$a10.3324/haematol.2023.282912$$n1$$p72-83$$tHaematologica$$v109$$x0390-6078$$y2024
000277758 909CO $$ooai:inrepo02.dkfz.de:277758$$pVDB
000277758 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000277758 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277758 9141_ $$y2023
000277758 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-03-30
000277758 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
000277758 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
000277758 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
000277758 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
000277758 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000277758 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000277758 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000277758 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-06-05T07:07:08Z
000277758 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-06-05T07:07:08Z
000277758 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2023-06-05T07:07:08Z
000277758 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000277758 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-23
000277758 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000277758 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-23
000277758 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000277758 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000277758 980__ $$ajournal
000277758 980__ $$aVDB
000277758 980__ $$aI:(DE-He78)C060-20160331
000277758 980__ $$aUNRESTRICTED